Close
Achema middle east
swop processing & packaging

USPTO issues notice of allowance for GW Pharmaceuticals Sativex formulation spray device

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Quantum Computing Advances Make Way for Lifesaving Therapies

The fact is that there is something very profoundly...

The USPTO has issued a notice of allowance for GW Pharmaceuticals’ patent application regarding Sativex formulation spray device.

The patent alleges a metered valve pump spray device comprising a liquid cannabis extract, in propylene glycol and ethanol, which is adapted to spray a dose towards a patient’s sublingual mucosa.

GW chief executive officer Justin Gover said the notice of allowance for the Sativex delivery device follows notice of allowance for method of sublingual delivery of the Sativex pharmaceutical formulation.

“Not only does GW have claims directed to the method of sublingual delivery of the Sativex formulation, but it also has claims directed to the device within which it is contained,” Gover added.

“In total, we now have seven different patent families containing one or more pending or issued patents relating to Sativex.” The issued patent is expected to expire in March 2021.

 

Latest stories

Related stories

Novartis-Argo $5.2 Licensing Deal for Heart Drugs

Argo Biopharmaceutical from China, which happens to be a...

The Shift Towards Real-World Evidence Clinical Development

The fact remains that the pharmaceutical spectrum happens to...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Quantum Computing Advances Make Way for Lifesaving Therapies

The fact is that there is something very profoundly...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »